^
Association details:
| Biomarker: | ASS1 negative |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | pegylated recombinant human arginase (BCT-100) (Arginase replacement) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma
Published date:
04/15/2021
Excerpt:
This is a single arm open-label Phase II trial to assess the potential clinical efficacy of PEG-BCT-100 in chemo naïve sorafenib-failure HCC patients....Post hoc analysis showed that duration of arginine depletion correlated with OS. For patients with available IHC results, 10 patients with ASS-negative tumour had OS of 35 weeks (95% CI: 8.3-78.0 weeks)...ASS-negative confers OS advantage over ASS-positive HCC.
DOI:
10.1007/s10637-021-01111-8
Trial ID:
